Ajanta Pharma has announced its earnings conference call schedule for Q3FY26 results discussion, filing the notification under Regulation 30 of SEBI listing requirements on January 12, 2026. The pharmaceutical company will release its unaudited financial results for the third quarter of fiscal year 2026 followed by an investor interaction session.

Conference Call Details

The earnings conference call is scheduled for January 30, 2026, providing investors and analysts an opportunity to engage with the company's leadership team regarding financial performance and business developments.

Dial-in Access Options

The company has arranged multiple access methods to accommodate participants from different regions. A Diamond pass registration system offers faster connectivity for convenience.

Primary Access Numbers

• Universal Access: (+91 22 6280 1542) and (+91 22 7115 8372)
• Diamond pass registration available for expedited access

International Toll-Free Numbers

• USA: 18667462133
• UK: 08081011573
• Hong Kong: 800964448
• Singapore: 8001012045

Registration Process

Participants can register through the Diamond pass link to receive a calendar invite with passcode and PIN number. The access credentials will be activated 30 minutes before the scheduled conference time. The registration system includes step-by-step instructions for dialing in and reconnecting if disconnected.

Post-Call Availability

The earnings call playback will be accessible on the company's website at www.ajantapharma.com within 120 minutes after the session concludes. A complete transcript of the conference call will also be made available on the same platform.

Investor Relations Contacts

For queries related to the earnings call, investors can reach out to the designated investor relations team:

• Rajeev Agarwal: rajeev.agarwal@ajantapharma.com
• Abhineet Kumar: abhineet.kumar@ajantapharma.com

The announcement was signed by Gaurang Shah, Sr. VP – Legal & Company Secretary, ensuring compliance with regulatory disclosure requirements.

Ajanta Pharma Limited , a prominent player in the pharmaceutical sector, has witnessed continued share pledging activities by its promoters. The latest disclosures show significant new pledge creations by key promoter Aayush Agrawal, adding to the series of recent transactions by promoters.

Latest Pledge Creation by Aayush Agrawal Trust

In the most recent disclosure dated December 31, 2025, Aayush Agrawal Trust reported the creation of a pledge on equity shares under SEBI SAST Regulations 2011. The transaction details are:

This follows another substantial pledge creation earlier in December, demonstrating ongoing financing activities by the promoter group.

Previous December 2025 Transactions

Prior to the latest disclosure, Aayush Agrawal had reported a major pledge creation on December 26, 2025, involving 16,02,500 shares for bank guarantee and increased loan purposes. Earlier in December 2025, Aayush Agrawal had also reported simultaneous pledge creation and release activities on December 17, 2025, involving pledging 6,38,500 shares while releasing 4,50,000 shares with Bajaj Finance Ltd.

Earlier Aayush Agrawal Activities

In October 2025, Aayush Agrawal had pledged 6,45,000 shares for new loan and additional margin purposes, disclosed on October 1, 2025, with multiple financial institutions including Deutsche Investments India Pvt Ltd, HSBC InvestDirect Financial Services India Ltd, and Jio Finance Ltd.

Ravi Agrawal's Share Transactions

In a separate disclosure dated October 3, 2025, Ravi Agrawal, another promoter of Ajanta Pharma, reported both creation and release of pledges:

Significant transactions included pledge creation of 10,50,000 shares with Emerging India Credit Opportunities Fund for business financing, along with multiple smaller transactions with various financial institutions.

Promoter Pledging Activity Summary

The recent series of pledging activities by Ajanta Pharma promoters demonstrates active financial management strategies. With multiple pledge creations by Aayush Agrawal Trust, including the latest 1,27,660 shares and earlier 16,02,500 shares in December 2025, the promoters continue to utilize their shareholdings for various financing requirements. These transactions are part of routine corporate financing activities and reflect ongoing business requirements including bank guarantees and loan facilities.